At this point, the disease progresses in about half of patients,25,26 metastasizing to involve other organs, such as bone, and leading ultimately to death. Each of these phases requires different diagnostic, surveillance, and treatment modalities, all designed to calibrate treatment to disease risk...
found a similar incidence of bone metastasis in lung and breast cancer and the regional distribution of metastasis was the same26. According to Macedo et al. the relative incidence of bone metastasis in patients with advanced metastatic disease is 65–75% in breast cancer and 30–40% in lung...
From a dataset of 20 million patients, we identified 1,045 patients diagnosed between January 2001 and December 2010 with bone metastasis (ICD 10: C795) following breast cancer (ICD 10: C50) with first-time cancer-related bisphosphonate prescriptions (ATC: M03B4). Of these, 763 patients ...
To determine brain metastasis in renal cancer, we first analysed autopsy results because autopsies offer an opportunity to study the distribution and frequency of metastases in different organ sites in a very late stage of tumour disease. Most frequent metastasis was seen in the lung. This high fr...
metastatic disease Patients, n (%) Unknown primary tumour (n = 395) Unknown primary tumour Ovary Colon and rectum Non-small cell lung Non-Hodgkin's lymphoma Buccal cavity and pharynx Pancreas Bone and soft tissue sarcoma Stomach, small intestine, hepatocellular liver, and other digestive system ...
in urban teaching hospitals.Elixhauser comorbidityscore consisted of 29 common comorbidities that could reflect the severity ofdisease burdens(excluded cancer) [23]. The principal diagnosis was categorized through the Clinical Classifications Software (CCS) for ICD-9-CM, which was a scheme that ...
This stage information is considered to be accurate since this is audited by humans; (ii) if the patient has two separate procedures with ICD9 diagnosis codes to indicate metastatic disease. For instance, 198.5 is “secondary malignant neoplasm of bone and bone marrow” and is a reliable ...
57,59,60,62 For example, in a CT26 model, the clinical activity of abemaciclib was dependent on immunity, and combination anti-PD-L1 plus abemaciclib resulted in superior disease control with complete responses. Of note, concurrent therapy was superior to sequential therapy in this model. A ...
Patients with primary and bone metastatic breast cancer have significantly reduced survival and life quality. Due to the poor drug delivery efficiency of anti-metastasis therapy and the limited response rate of immunotherapy for breast cancer, effective treatment remains a formidable challenge. In this ...
Compared with the paclitaxel group, a significantly higher proportion of patients in the nab-paclitaxel group had bone metastases. The percentage of patients using adjuvant taxane treatment within 1 year from the diagnosis of metastatic disease was significantly higher in the nab-paclitaxel group ...